Latest News & Features
Americas
Pharmaceutical companies MSD and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia should be reversed because the circumstances of the class members do not justify an award of class status. 7 January 2021
Asia
India has granted emergency approval to COVID-19 vaccines developed by AstraZeneca and Oxford University and one from the state-run institute Bharat Biotech, ahead of a huge immunisation drive that is planned to begin this week. 5 January 2021
Americas
Teva Pharmaceuticals has failed to redefine its multiple sclerosis drug Copaxone as a biological product instead of a drug, after the US District Court for the District of Columbia dismissed its efforts as “uncompetitive” on December 31. 5 January 2021
Americas
Aurobindo’s subsidiary Eugia allegedly infringed two patents for an injectable treatment for reducing the risk of premature birth, according to a lawsuit by Covis Pharma, a Luxembourg-based unit of Apollo Global Management. 5 January 2021
Americas
One of the architects of the Hatch-Waxman Act has urged judges to reverse a decision which he says nullifies a key provision of the generic drug legislation. 5 January 2021
Americas
Canadian medical cannabis company Canopy Growth has accused GW Pharma of using a patented technological process to produce its flagship epilepsy treatment, Epidiolex, without authorisation. 24 December 2020
Americas
A manufacturer of healthcare products including personal protective equipment has accused a newly incorporated company of trying to confuse consumers during the Covid-19 pandemic. 24 December 2020
Americas
A US federal appeals court has upheld a 42-month prison sentence for an ex-employee of DuPont Industrial Biosciences who stole trade secrets from the firm. 24 December 2020
Americas
Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology. 24 December 2020
Americas
Biogen has lost its long-standing fight to recover billions of dollars in royalties from the sale of a multiple sclerosis (MS) drug, after the US Court of Appeals for the Federal Circuit rejected Biogen’s request that it reconsider its own ruling. 22 December 2020